Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody- drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study
D O I:
10.1158/1538-7445.AM2023-CT204